Another trial tested semaglutide in people with normal kidneys, mild renal impairment, moderate renal impairment, and even severe kidney disease
Retatrutide Side Effects Common: Nausea: ~43% at 12mg (TRIUMPH-4) Diarrhea: ~33% Vomiting: ~20% Dysesthesia: 20.9% at 12mg (abnormal skin sensations unique to retatrutide) Discontinuation due to adverse events: 11.3% (TRIUMPH-1, general obesity) / 18.2% (TRIUMPH-4, osteoarthritis population)
At validated doses, GLP-1 therapy commonly reduces HbA1c by roughly 1.01.5 percentage points in clinical trials
Why is it appropriate for my situation
As additional trials report, the picture of retatrutide efficacy and safety across different populations and indications will become increasingly complete
As does individualized care